HER2/CEP17 FISH Ratio for Predicting Pathologic Complete Response Following Neoadjuvant Dual Anti-HER2 Therapy in Patients With HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
Oncologist 2022 Dec 10;[EPub Ahead of Print], EM Lander, KC Rappazzo, LC Huang, JR Hu, H Chen, Y Shyr, VG AbramsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.